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Abstract
Background: Fluid administration to critically ill patients remains the subject of considerable controversy. While
intravenous fluid given for resuscitation may be life-saving, a positive fluid balance over time is associated with
worse outcomes in critical illness. The aim of this systematic review is to summarise the existing evidence regarding
the relationship between fluid administration or balance and clinically important patient outcomes in critical illness.
Methods: We will search Medline, EMBASE, the Cochrane Central Register of Controlled Trials from 1980 to the present
and key conference proceedings from 2009 to the present. We will include studies of critically ill adults and children with
acute respiratory distress syndrome (ARDS), sepsis and systemic inflammatory response syndrome (SIRS). We will include
randomised controlled trials comparing two or more fluid regimens of different volumes of fluid and observational
studies reporting the relationship between volume of fluid administered or fluid balance and outcomes
including mortality, lengths of intensive care unit and hospital stay and organ dysfunction. Two independent
reviewers will assess articles for eligibility, data extraction and quality appraisal. We will conduct a narrative
and/or meta-analysis as appropriate.
Discussion: While fluid management has been extensively studied and discussed in the critical care literature,
no systematic review has attempted to summarise the evidence for post-resuscitation fluid strategies in critical
illness. Results of the proposed systematic review will inform practice and the design of future clinical trials.
Systematic review registration: PROSPERO CRD42013005608. (http://www.crd.york.ac.uk/PROSPERO/)
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Background
Description of the condition
Despite a vast range of underlying aetiologies for critical
illness, patients who are critically ill have numerous fea-
tures in common and often share a similar approach to
management. For this review, however, we have selected
critical illnesses for which clear definitions exist—acute
respiratory distress syndrome (ARDS), sepsis and sys-
temic inflammatory response syndrome (SIRS)—since
‘critical illness’ is a poorly defined entity. Each of these
terms represents a common syndrome found in critically ill
patients with a range of underlying aetiologies. The major-
ity of patients who are admitted to an intensive care unit
will have one or more of these syndromes. ARDS encom-
passes the older term ‘acute lung injury (ALI)’ and refers to
an acute inflammatory process involving both lungs result-
ing in hypoxaemia and low lung compliance. ARDS occurs
in around 14 % of patients admitted to intensive care units
(ICUs) [1] and is defined most recently by the Berlin con-
sensus criteria [2]. SIRS is a general term describing a con-
stellation of features which are consistent with generalised
inflammation and which may result from a range of insults
including infection, major trauma, burns, pancreatitis and
brain injury. SIRS has been reported to occur in up to 98 %
of patients in the intensive care environment [3]. Sepsis is
defined as infection with SIRS and is found in approxi-
mately 37 % of ICU patients [4]. By using as our study
population patients with each of these syndromes, we aim
to set clear boundaries for inclusion and exclusion of stud-
ies while maximising the generalisability of our findings to
critically ill patients as far as possible.
Description of the intervention
Intravenous fluid administration is one of the most com-
mon interventions in critical care. In patients with hypo-
volaemia or pathological vasodilation from states such as
sepsis, it is widely held that early and rapid administra-
tion of intravenous fluid to restore circulating blood vol-
ume and blood flow to tissues is life-saving, although
that view has recently been challenged [5]. The volume
of intravenous fluid which may be given is highly vari-
able and is dependent on the endpoints used to assess
tissue perfusion, among other factors [6].
Despite large volumes of literature on the subject, the
optimal targets for fluid resuscitation remain unclear, while
fluid is also administered to critically ill patients as main-
tenance fluid, drug diluent, nutrition and blood products.
Moreover, in critical illness states, sodium and water re-
tention is common due to prevailing endocrine influ-
ences and to the frequent occurrence of acute kidney
injury. The combination of fluid administration and lim-
ited excretion typically leads to a positive fluid balance of
many litres over a period of days, which is compounded by
fluid leak from capillaries into the interstitium to produce
oedema of peripheries, lungs, and other organs [7].
The paradox is that while fluid resuscitation early in
critical illness is thought to be life-saving, a positive cu-
mulative fluid balance is associated with mortality in pa-
tients with septic shock [4, 8] and in subgroups with
acute kidney injury (AKI) [9–11] or ARDS [12–14]. In con-
trast, in the setting of ARDS, diuretic use [12] and restrict-
ive fluid management are associated with lower mortality
and faster liberation from mechanical ventilation, respect-
ively [14]. At present, there is equipoise as to whether the
association between fluid accumulation and poor outcomes
represents a causal relationship, or is simply a marker of
more severely ill patients who require more fluid resuscita-
tion, are oliguric, or who fail to tolerate the use of diuretics
or ultrafiltration to remove accumulated fluid, a strategy
known as deresuscitation.
How the intervention might work
As a result of these seemingly conflicting findings, a
multi-phasic approach to fluid therapy has been pro-
posed. It is postulated that while fluid resuscitation early
in the course of critical illness to optimise cardiac output
and tissue perfusion is beneficial, a conservative fluid
management strategy or active deresuscitation in the
later phase of critical illness may improve organ function
and survival by minimising the harmful effects of tissue
oedema [15]. However, a post hoc analysis of ARDS sur-
vivors from the Fluids and Catheter Treatment Trial
[14] found a conservative fluid management strategy to
be associated with long-term cognitive impairment [16].
Thus, the risks and benefits of a conservative fluid strat-
egy, along with the applicability of this finding to pa-
tients without ARDS, remain uncertain.
Why it is important to do this review
Fluid management is a key element of the management
of patients who are critically ill. Optimisation of oxygen
delivery to tissues requires fluid administration, while a
growing body of observational literature points to a con-
sistent association between fluid overload and worse pa-
tient outcomes. Developing our understanding of the
benefits and harms of fluid therapy is a fundamental
question of major relevance to the practice of critical
care medicine.
Review question
In adult and paediatric patients with sepsis, SIRS or ARDS
who are not in the resuscitation phase of critical illness, is a
more restrictive fluid regimen/active deresuscitation strat-
egy associated with an improvement in clinically important
outcomes?
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Sub-questions
1. What criteria are used to judge suitability for fluid
restriction or deresuscitation?
2. What methods are used to restrict fluid or
deresuscitate?
3. What contra-indications to deresuscitation are applied?
Methods
Types of studies
We will include:
1. All clinical trials (randomised or quasi-randomised)
comparing two or more fluid regimens in which dif-
ferent volumes of fluid are administered or different
fluid balance is achieved, regardless of techniques
used to guide fluid therapy
2. Observational studies in which fluid management is
a major focus of the study and in which the study
reports the relationship between the volume of fluid
administered or fluid balance and one or more of
the outcomes above
We will exclude case series or reports, observational
studies in which the total number of subjects is less than
50, and studies subject to post-publication investigation
or retraction.
Types of participants
We will include studies of adult and paediatric patients.
Since ‘critical illness’ is a poorly defined entity, we will
include critical illnesses for which widely accepted defi-
nitions exist: ARDS, sepsis and SIRS in this review. We
will exclude studies involving animals, or in which the
patient population is made up predominantly of neo-
nates, post-cardiac surgery or heart failure patients or
perioperative patients.
Types of intervention(s) and comparators
Studies will be included if the intervention involved mini-
misation of fluid intake or active deresuscitation using di-
uretics or ultrafiltration and if the comparator was standard
care or liberal fluid strategy.
We will exclude studies in which fluid management is
only one aspect of a haemodynamic intervention strat-
egy or in which the main comparison is between two or
more different types of fluid.
Types of outcome measures
1. Primary outcome:
Mortality (all cause, at the most protracted time
point reported to a maximum of 90 days)
2. Secondary outcomes:
Length of ICU stay, length of hospital stay
Organ dysfunction (multiple organ dysfunction
score (MODS), sequential organ failure score
(SOFA) or simplified acute physiology score
(SAPS II))
Renal dysfunction (AKI incidence, renal replacement
therapy use)
Respiratory dysfunction (incidence of new ARDS,
ventilator-free days)
Cognitive function (author-defined)
Long-term mortality (>90 days)
Search strategy
We will search the following databases for relevant studies
from 1980 onwards with no language constraints: Medline,
EMBASE, and Cochrane Central Register of Controlled
Trials (CENTRAL). In addition, we will undertake a
manual search of indexed abstracts from the following
key conference proceedings from 2009 to the present: the
American Thoracic Society, Society of Critical Care Medi-
cine, and European Society of Intensive Care Medicine
Annual Congresses and the International Symposium on
Intensive Care and Emergency Medicine.
Key search terms will include the following: fluid ther-
apy, diuretics, furosemide, ultrafiltration, water-electrolyte
balance, systemic inflammatory response syndrome, sep-
sis, acute lung injury, respiratory distress syndrome and
adult. Our Medline search strategy (Additional file 1) will
be adapted for searches in other databases.
Citation management and screening
Citations will be stored using Microsoft Excel software
(Microsoft Corporation, Redmond, WA), and duplicates
will be removed. Studies will be screened initially accord-
ing to title and abstract by two authors independently, and
those not meeting the criteria will be discarded. Disagree-
ments will be resolved by discussion and referral to a third
author if necessary.
After this initial stage, the full text of all remaining
studies will be reviewed by two authors independently
for inclusion or exclusion in the final study. As before,
disagreements will be resolved by discussion and referral
to a third author if necessary.
Data abstraction
For interventional studies, we will record information on
the type and setting of the study, number of subjects, pa-
tient characteristics, nature of the intervention(s) in each
group and outcomes as described above. After piloting,
data will be extracted independently by two authors using
standardised report forms (Additional file 2). Adjudication
by a third author will be used if necessary.
For observational studies, a minimal dataset will in-
clude study details, patient characteristics, description of
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the intervention(s), main outcomes and adverse events.
Efforts will be made to contact the authors of primary
studies to provide missing data where necessary.
Assessment of risk of bias
The quality of included studies will be independently
assessed by two authors and verified by a third if neces-
sary. Study quality of RCTs will be assessed using the
domain-based evaluation recommended by the Cochrane
Collaboration [17]. The domains include:
1. Random sequence generation
2. Allocation concealment
3. Blinding
4. Incomplete outcome data
5. Selective reporting
6. Other bias
For each domain, we will assign a judgement regarding
the risk of bias as high, low or unclear [17]. We will at-
tempt to contact the trial corresponding author for clari-
fication when insufficient detail is reported to assess risk
of bias. Once we have consensus on the quality assess-
ment of the six domains for eligible studies, we will as-
sign them to the following categories:
1. Low risk of bias: describes studies for which all
domains are scored as ‘yes’
2. Moderate risk of bias: describes studies for which
one or more domains are scored as unclear or one
domain is scored as ‘no’
3. High risk of bias: describes studies for which more
than one domain is scored as ‘no’
We will construct a ‘Risk of Bias’ table to present the
results. We will use the assessment of risk of bias to per-
form sensitivity analyses based on methodological qual-
ity as necessary.
For observational studies, the Newcastle-Ottawa Scale
will be used to assess study quality. Domains used to
judge the quality of cohort studies include:
1. Representativeness of the exposed cohort
2. Selection of the non-exposed cohort
3. Ascertainment of exposure
4. Demonstration that outcome of interest was not
present at the start of the study
5. Comparability of cohorts on the basis of the design
or analysis
6. Assessment of outcome
Case-control studies will be assessed using the appro-
priate version of this scale. Reporting of all observational
studies will include this assessment of study quality.
Data synthesis
If two or more randomised controlled trials are available
for an outcome, their results will be combined in a
meta-analysis using Review Manager (RevMan 5.3) soft-
ware (Nordic Cochrane Centre, Cochrane Collaboration)
on an intention-to-treat basis if appropriate to do so.
We will not attempt meta-analysis of observational stud-
ies. If heterogeneity is very high (i.e. >90 %) and is unex-
plained by pre-planned subgroup analysis, we will report
results narratively. If there are data from only one study for
an outcome, the results will be reported narratively. For
continuous data, we will use the inverse variance method,
while the Mantel-Haenszel method will be employed for di-
chotomous data. For key outcomes, we will evaluate our
confidence in the body of evidence according to the
GRADE scale ([18]).
Measures of effect for dichotomous data
Where possible, the treatment effect for dichotomous out-
comes will be expressed as odds ratios with 95 % confi-
dence intervals. If time-to-event data is available, we will
use hazard ratios rather than risk ratios. We will use the
Peto method to estimate the odds ratios for rare outcomes.
Measures of effect for continuous data
The treatment effect for continuous outcomes will be
expressed as mean difference with 95 % confidence in-
tervals. Where different scales are used, standardised
mean difference (SMD) with 95 % confidence intervals
will be used to express treatment effect.
Measures of effect for ordinal data
We will analyse longer ordinal scales as continuous data,
while shorter ordinal scales will be abbreviated to di-
chotomous data. Treatment effects will then be assessed
as described for each type of data.
Unit of analysis issues
Individual participants in each trial arm will comprise
the unit of analysis. We anticipate that all trials included
in the meta-analysis will have a parallel group design,
and thus, no adjustment will be necessary for crossover
or clustering.
Missing data
Where possible, we will contact trial authors to request
missing data.
Assessment of heterogeneity
We will assess qualitative heterogeneity of the included
studies and only combine studies whose participants are
sufficiently similar, such that combining data across
studies leads to a meaningful result. Statistical hetero-
geneity will be informally evaluated from forest plots of
Silversides et al. Systematic Reviews  (2015) 4:162 Page 4 of 6
the study estimates and more formally using the chi2 test
(P value <0.1, significant heterogeneity) and I2 statistic
(I2 > 50 % = significant heterogeneity) [17].
Assessment of reporting biases
If a sufficient number of studies is identified (n > 10),
we will investigate reporting biases through the use of
a funnel plot.
Sensitivity and subgroup analysis
If appropriate, we will investigate the influence of meth-
odological quality on results by examining the effect of
excluding studies at high or unclear risk of bias, and if
necessary, we will undertake sensitivity analysis to assess
the effect of excluding individual studies.
If sufficient studies are available, we will undertake sub-
group analyses for adults, children, all patients with ALI or
ARDS and all patients with sepsis, SIRS or septic shock.
Standards
Reporting will conform to Preferred Reporting Items for
Systematic Reviews and Meta Analyses (PRISMA) stan-
dards (Additional file 3) [19]. This systematic review has
been registered with PROSPERO, an international pro-
spective register of systematic reviews (http://www.crd.yor-
k.ac.uk/PROSPERO/).
Discussion
While fluid management has been extensively studied and
discussed in the critical care literature, no systematic re-
view to date has attempted to summarise the evidence for
a greater or lesser fluid volume or balance at different time
points in critical illness, and this remains an area of debate
among clinicians and researchers. It is hoped that in sum-
marising the current evidence, this systematic review will
inform practice and future trial design.
Additional files
Additional file 1: Medline search strategy. Modified versions of this
strategy will be used for other databases.
Additional file 2: Data abstraction form for randomised controlled
trials. A modified version of this form will be used for observational
studies.
Additional file 3: Checklist of Preferred Reporting Items for
Systematic Reviews and Meta-analysis Protocols (PRISMA-P).
Reporting guideline for systematic review protocols.
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